Is Density Spectral Array Display Along With Bispectral Index Superior to the Display of Bispectral Index Alone
NCT ID: NCT07232160
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
70 participants
OBSERVATIONAL
2026-06-30
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bispectral Index (BIS) Versus Electronic Alerts in the Prevention of Anesthesia Awareness: the Michigan Awareness Control Study
NCT00689091
Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era
NCT04661423
Comparability of Bispectral Index and NeuroSENSE in Aged Patients
NCT02015741
Evaluation of RDS MultiSense® in Desaturation Analysis in Healthy Volunteers
NCT05044585
Data-driven Development of a Core Dataset for Difficult Airway Alerts
NCT07275567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis: In comparison to monitor 1 (BIS only), monitor 2 (DSA + BIS) will have higher sensitivity and specificity to detect recovery
Objectives:
Investigators will prospectively measure the sensitivity and specificity of monitor 1 versus monitor 2 in patients older than 65 years receiving propofol-based TIVA.
Methods:
Investigators will recruit 70 participants from the Royal Brisbane and Women's Hospital (RBWH) who are aged 65 years or older and scheduled for elective endovascular or endoscopic urologic procedures.
Investigators aim to determine whether the display of DSA can enhance the sensitivity and specificity of depth of anesthesia monitors in detecting sudden changes in anesthetic depth in older patients. This may enhance the detection of inadequate administration or delivery of propofol and may lower the incidence of unintended awareness under general anesthesia in that age group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Primary cohort
* Age ≥ 65 years undergoing elective procedures of 1-3 hours' duration requiring GA.
* Procedures in which a DoA monitor can be applied to the forehead.
* Patients receiving intravenous propofol and opiate anesthesia using supraglottic airway device.
* Patient able to provide informed consent.
Depth of anesthesia monitoring using processed EEG
Comparison of processed EEG monitor (Bispectral index) with and without Density spectral array
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Depth of anesthesia monitoring using processed EEG
Comparison of processed EEG monitor (Bispectral index) with and without Density spectral array
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Procedures in which a DoA monitor can be applied to the forehead.
* Patients receiving intravenous propofol and opiate anaesthesia using supraglottic airway device.
* Patient able to provide informed consent.
Exclusion Criteria
* Administration of inhaled anaesthetic agents or nitrous oxide
* Administration of muscle relaxation
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
The University of Queensland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Boules, MB BCh
Role: PRINCIPAL_INVESTIGATOR
The University of Queensland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/HE000173
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.